Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

11.12
+1.5115.71%
Post-market: 11.330.2100+1.89%19:56 EDT
Volume:198.09K
Turnover:2.12M
Market Cap:465.20M
PE:-1.59
High:11.28
Open:9.76
Low:9.61
Close:9.61
Loading ...

Zenas BioPharma to Present at Jefferies Conference

TIPRANKS
·
04 Jun

Zenas BioPharma Inc. to Present at Jefferies Global Healthcare Conference

Reuters
·
29 May

Zenas BioPharma Reports Q1 2025 Financial Results

TIPRANKS
·
17 May

Zenas BioPharma Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
16 May

Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating

TIPRANKS
·
16 May

BRIEF-Zenas Biopharma Reports First Quarter 2025 Financial Results

Reuters
·
15 May

Zenas BioPharma Q1 EPS $(0.80) Beats $(1.05) Estimate, Sales $10.00M Beat $1.67M Estimate

Benzinga
·
15 May

Zenas Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

THOMSON REUTERS
·
15 May

Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Simply Wall St.
·
23 Apr

Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before June 16, 2025 to Discuss Your Rights – ZBIO

TIPRANKS
·
18 Apr

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
18 Apr

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
18 Apr

Zenas BioPharma appoints Haley Laken as CSO

TIPRANKS
·
07 Apr

Zenas Biopharma Appoints Haley Laken, Ph.d., as Chief Scientific Officer

THOMSON REUTERS
·
07 Apr

Press Release: Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Dow Jones
·
07 Apr

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Dow Jones
·
21 Mar

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Benzinga
·
21 Mar

Zenas BioPharma Initiated at Outperform by Wedbush

Dow Jones
·
20 Mar

Wedbush Initiates Zenas BioPharma at Outperform With $35 Price Target

MT Newswires Live
·
20 Mar

Zenas BioPharma initiated with an Outperform at Wedbush

TIPRANKS
·
20 Mar